Nature ProtocolsGenomicsPeer-reviewed journal article
A guide to performing Polygenic Risk Score analyses
Shing Wan ChoiiD, Timothy Shin Heng MakiD, Paul F. O’ReillyiD
Abstract
The application of polygenic risk scores (PRS) has become routine across genetic research. Among a range of applications, PRS are exploited to assess shared aetiology between phenotypes, to evaluate the predictive power of genetic data for use in clinical settings, and as part of experimental studies in which, for example, experiments are performed on individuals, or their biological samples (eg. tissues, cells), at the tails of the PRS distribution and contrasted. As GWAS sample sizes increase and PRS become more powerful, they are set to play a key role in personalised medicine. However, despite the growing application and importance of PRS, there are limited guidelines for performing PRS analyses, which can lead to inconsistency between studies and misinterpretation of results. Here we provide detailed guidelines for performing polygenic risk score analyses relevant to different methods for their calculation, outlining standard quality control steps and offering recommendations for best-practice. We also discuss different methods for the calculation of PRS, common misconceptions regarding the interpretation of results and future challenges.
- organism: human
- assay: GWAS summary statistics
- research focus: polygenic risk
- research focus: benchmarking
- approach: statistical model
- approach: simulation
In-depth summary
Claude Opus 5.5 · xhigh effort · 8 Nov 2026 · from the full text of version 1 (14 Sept 2018) · CC BY 4.0
Best-practice guidance for polygenic risk score (PRS) analysis: PRS-specific quality control, shrinkage and linkage disequilibrium handling, liability-scale R^2, overfitting control, and UK Biobank power examples.
Polygenic risk scores (PRS) are used to test shared aetiology, judge clinical predictive value and pick individuals with extreme scores for experiments, yet guidelines are scarce and no summary contrasted the main approaches, so studies are inconsistent and results get misread. This guide brings together PRS-specific quality control (QC), calculation options, association testing and interpretation pitfalls, whatever the method or application.
Key results
ClaimedPRS analyses need QC beyond standard GWAS filters because errors add up across SNPs. Check file integrity and genome build, confirm the effect allele, drop strand-ambiguous and duplicate SNPs, check sex, and remove base/target sample overlap and close relatives.
These are recommendations, not empirical tests: remove all A/T and C/G SNPs rather than aligning them by allele frequency; exclude 1st/2nd degree relatives across base and target; treat a base GWAS with hsnp^2 < 0.05 (from LD Score regression or LDAK) with caution. · 2. Quality Control of Base and Target data; Ambiguous SNPs; Relatedness; Heritability check
ClaimedPicking the most predictive P-value threshold (or any tuning parameter) trains the model on the target sample, so a true out-of-sample check needs a third dataset. Using one arbitrary threshold with no optimisation risks underfitting.
No data are given. The suggested fallbacks are repeated partitioning of the target (e.g. 10-fold cross-validation) or empirical P-values from permutation. The authors argue the latter keeps type 1 error appropriate when the aim is hypothesis testing rather than prediction. · 4.4 Overfitting in PRS association testing
SuggestedIn simulation, the Lee et al liability-scale pseudo-R^2 corrects for case/control ratios that differ from disease prevalence, whereas Nagelkerke R^2 is biased by that ascertainment.
2,000,000 individuals were simulated with a normal phenotype driven partly by a normal predictor; case status followed a liability threshold model; 5,000 cases and 5,000 controls were sampled. Both pseudo-R^2 values were compared with an empirical R^2 from linear regression. The text gives no error sizes. · 4.1 Association and goodness-of-fit metrics; Figure legends
SuggestedA real-data reference shows how PRS variance explained and association P-values change with validation sample size for UK Biobank traits of high, medium and low heritability.
Traits: height (h^2 = 0.49), Forced Volume Capacity (h^2 = 0.23) and hand grip (h^2 = 0.11). Two random sets of 100,000 individuals served as base and target; validation sets ran from 50 to 3000 individuals, repeated 5 times. Results are shown only in Figure 4, not in the text. · 4.5 Power and accuracy of PRS: target sample…; Figure legends
ClaimedBecause PRS aggregate the estimated effects of many null SNPs, population stratification is potentially a greater problem for them than for GWAS. Correlated allele-frequency and environmental differences between base and target can create spurious associations even if the GWAS corrected for structure perfectly.
This is a conceptual argument without data. It advises many principal components when base and target are genetically similar, extreme caution across populations, and checking PRS distributions, since mixed ancestry or correlated SNPs can yield non-normal scores. · 3.4 Population structure and global…; 4.3 PRS distribution
Methods, data and reproducibility
Narrative protocol review in three parts: base/target quality control; PRS construction (shrinkage versus P-value thresholding, clumping versus LD modelling, units, cross-trait use); and association testing and interpretation. A pseudo-R^2 simulation and UK Biobank validation-size experiments illustrate the guidance.
- Simulated population with a normally distributed phenotype and predictor; case/control status assigned under a liability threshold model, then a balanced case/control subsample drawn · n = 2,000,000 simulated; 5,000 cases and 5,000 controls sampled
- UK Biobank height, Forced Volume Capacity (FVC) and hand grip strength, randomly split into base GWAS, target and validation sets · human (UK Biobank) · n = 100,000 base; 100,000 target; validation 50 to 3000
- Methods & tools
- PLINK, md5sum, LiftOver, LD Score regression (LDSC), LDAK, GCTA, LDpred, LASSO / ridge regression shrinkage, Clumping + P-value thresholding (C+T), Nagelkerke pseudo-R^2, Lee et al liability-scale pseudo-R^2, Permutation-based empirical P-values
- Reproducibility gaps
- No code, scripts, software versions or repository are given for the simulation or the UK Biobank analyses, and the UK Biobank application or access route is not stated.
Limitations (6)
- The guide deliberately does not compare the predictive power of different PRS methods or review PRS applications, leaving both to other publications. · stated by the authors
- The UK Biobank analysis covers only three traits and one base GWAS size; the authors say it gives only a very limited indication of PRS performance. · stated by the authors
- Sex chromosomes are usually left out of PRS because there is no consensus on how to analyse them in GWAS, so some predictive power is given up. · stated by the authors
- No correction exists for complex base/target sample-overlap scenarios, and clumping relies on arbitrarily chosen LD correlation thresholds; the authors flag both for future methods work. · stated by the authors
- Standard PRS pipelines treat a target trait that differs from the base trait the same way despite uneven genetic sharing, and PRS reliability across populations is still unresolved. · stated by the authors
- Most recommendations, such as dropping all ambiguous SNPs and the hsnp^2 cutoff, are expert opinion without head-to-head testing, and the simulation and UK Biobank results are not quantified in the text. · noted in this summary
Read this if you are setting up a PRS study and want a checklist for base/target QC, threshold or shrinkage choices, pseudo-R^2 reporting on the liability scale, and avoiding overfit associations.
- Citations
- 1,955
- FWCI
- 32.66
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Improving reporting standards for polygenic scores in risk prediction studies
Hannah Wand, Samuel A. Lambert, … Genevieve L. Wojcik·NaturePeer-reviewed·Mar 10, 2021
- Expert Perspectives on Clinical Laboratory Accreditation for Polygenic Risk Scores
Courtney K. Wallingford, Tenielle Clinch, … Tatiane Yanes·medRxiv·Jul 23, 2025
- Implementation of Individualised Polygenic Risk Score Analysis: A Test Case of a Family of Four
Manuel Corpas, Karyn Mégy, … Edmund Lehmann·BMC Medical GenomicsPeer-reviewed·Oct 3, 2022
- A systematic framework for assessing the clinical impact of polygenic risk scores
Scott Kulm, Andrew R. Marderstein, … Olivier Elemento·medRxiv·Apr 6, 2020
- Positioning Personal Polygenic Risk score against the population background.
Ganna Leonenko, Emily Ann Baker, … the Alzheimer’s Disease Neuroimaging Initiative·bioRxiv·Oct 24, 2019
- Polygenic risk score prediction accuracy convergence
Léo Henches, Jihye Kim, … Hugues Aschard·Human Genetics and Genomics AdvancesPeer-reviewed·May 14, 2025